CYPHERPUNK TECHNOLOGIES INC. 8K

Cypherpunk Technologies’ subsidiary Leap Therapeutics reported publication of Phase 2 DeFianCe trial data showing baseline plasma DKK1 as a predictive biomarker for enhanced benefit from sirexatamab in DKK1‑high second‑line metastatic colorectal cancer patients, underpinning plans for a biomarker‑selected Phase 3 trial.

On August 12, 2026, Leap Therapeutics, Inc., the biotechnology subsidiary of Cypherpunk Technologies Inc. (Nasdaq: CYPH), announced that peer‑reviewed results from its randomized Phase 2 DeFianCe trial of sirexatamab (DKN‑01) in second‑line metastatic colorectal cancer were published in Clinical Cancer Research, showing that higher baseline plasma DKK1 levels predict greater clinical benefit from adding sirexatamab to standard chemotherapy and bevacizumab, particularly in DKK1‑high patients, and supporting plans for a biomarker‑selected Phase 3 registrational trial while noting that the overall intent‑to‑treat primary PFS endpoint was not met and that safety was generally comparable to control.

Filing Facts

CIK

1509745

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-094445

Alert Tier

6